NMS·Healthcare·$1.9B·#291 / 520 in Healthcare
ZYME Zymeworks Inc.
39HIGH RISK
CATEGORY BREAKDOWN
GROWTH62
QUALITY0
STABILITY66
VALUATION7
GOVERNANCE40
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+38.9%
62
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
15 months
52
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
6.8%
95
< 25% strong
Price / Sales
Market cap relative to trailing revenue
23.0x
7
< 3x strong
Rule of 40
Growth rate plus operating margin
-48
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
1.3%
10
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-3.2%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ZYME WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
4 Best Small-Cap Synthetic Biology Stocks — May 2026May 2, 2026SCORE ALERT
Get notified when ZYME's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.